NURIX THERAPEUTICS, INC. Debt Securities Available For Sale Excluding Accrued Interest
NURIX THERAPEUTICS, INC. (NRIX) had Debt Securities Available For Sale Excluding Accrued Interest of $422.55 million as of 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Balance Sheet › Assets
us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest · last filed 2026-07-09
- 2026-05-31: Debt Securities Available For Sale Excluding Accrued Interest $422.55M.
- 2026-02-28: Debt Securities Available For Sale Excluding Accrued Interest $536.50M.
- 2025-11-30: Debt Securities Available For Sale Excluding Accrued Interest $587.35M.
- 2024-11-30: Debt Securities Available For Sale Excluding Accrued Interest $589.97M.
| Period end | Debt Securities Available For Sale Excluding Accrued Interest |
|---|---|
| 2026-05-31 | $422.55M 10-Q · filed 2026-07-09 |
| 2026-02-28 | $536.50M 10-Q · filed 2026-04-08 |
| 2025-11-30 | $587.35M 10-Q · filed 2026-07-09 |
| 2024-11-30 | $589.97M 10-K · filed 2026-01-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |